Introduction {#acn3263-sec-0005}
============

Myoclonus‐dystonia (M‐D) is a rare hyperkinetic movement disorder typically characterized by myoclonus of the trunk and upper limbs in conjunction with dystonia of the neck or hands (writer\'s cramp).[1](#acn3263-bib-0001){ref-type="ref"}, [2](#acn3263-bib-0002){ref-type="ref"} Onset of motor symptoms is usually in the first two decades of life and are typically alcohol responsive. A proportion of M‐D cases are caused by mutations in the epsilon‐sarcoglycan gene (*SGCE*), which encodes the epsilon‐sarcoglycan protein.[3](#acn3263-bib-0003){ref-type="ref"} More than 40 different point mutations have now been identified, these resulting in proteosomal degradation and failure of expression of the mutated protein at the cell‐surface membrane.[4](#acn3263-bib-0004){ref-type="ref"}

Psychiatric symptoms have been reported to be prevalent amongst *SGCE* mutation‐positive cases.[5](#acn3263-bib-0005){ref-type="ref"}, [6](#acn3263-bib-0006){ref-type="ref"} Depression, anxiety disorders and obsessive‐compulsive disorder (OCD)[7](#acn3263-bib-0007){ref-type="ref"}, [8](#acn3263-bib-0008){ref-type="ref"}, [9](#acn3263-bib-0009){ref-type="ref"} have been frequently and repeatedly reported whereas other psychiatric diagnoses, for example, psychosis,[10](#acn3263-bib-0010){ref-type="ref"} schizophrenia,[7](#acn3263-bib-0007){ref-type="ref"} schizoaffective disorder,[11](#acn3263-bib-0011){ref-type="ref"} Attention Deficit Hyperactivity Disorder (ADHD)[12](#acn3263-bib-0012){ref-type="ref"}, and Anorexia Nervosa[13](#acn3263-bib-0013){ref-type="ref"} have been described predominantly in single case reports. More recently, larger cohort studies have used systematic and standardized methods to compare results from *SGCE* mutation‐positive M‐D cohorts to control groups, finding OCD, in particular compulsivity,[7](#acn3263-bib-0007){ref-type="ref"} and anxiety‐related disorders to be the most prominent reported neuropsychiatric features.[8](#acn3263-bib-0008){ref-type="ref"}

This study combines previously collected standardized data from four international centers (Netherlands, United Kingdom, United States, and Germany; see Table [1](#acn3263-tbl-0001){ref-type="table-wrap"} for an overview of the clinical centers involved) to form the largest single collection of psychiatric data from *SGCE* mutation carriers. Given the increasing recognition of nonmotor symptoms as a comorbid feature of dystonic disorders, this large cohort allows further assessment of the type and frequency of psychiatric symptoms in M‐D populations as well as another opportunity to examine whether these symptoms represent a pleiotropic function for the epsilon‐sarcoglycan protein or a secondary consequence of the motor disorder.

###### 

Demographic features of the study population

  Demographics                                                                                                                         MC (*n* = 132)            NMC (*n* = 38)            NC (*n* = 137)            Total (*n* = 307)
  ------------------------------------------------------------------------------------------------------------------------------------ ------------------------- ------------------------- ------------------------- -------------------------
  Gender                                                                                                                                                                                                             
  Male (%)                                                                                                                             70 (53)                   22 (58)                   48 (35)                   140 (46)
  Female (%)                                                                                                                           62 (47)                   16 (42)                   89 (65)                   167 (54)
  Mean age at examination (SD)                                                                                                         40.5 years (17.0 years)   50.4 years (17.1 years)   41.2 years (14.0 years)   42.1 years (16.1 years)
  Age at onset of motor symptoms (*n* %)                                                                                                                                                                             
  \<18 years                                                                                                                           65 (49)                   --                        --                        65 (21)
  18--30 years                                                                                                                         4 (3)                     --                        --                        4 (1.3)
  30--40 years                                                                                                                         1 (0.8)                   --                        --                        1 (0.3)
  40--50 years                                                                                                                         1 (0.8)                   --                        --                        1 (0.3)
  Unknown                                                                                                                              68 (52)                   --                        --                        68 (22)
  Number of cases per center (%)                                                                                                                                                                                     
  Academic Medical Centre, Amsterdam, the Netherlands[8](#acn3263-bib-0008){ref-type="ref"}, [14](#acn3263-bib-0014){ref-type="ref"}   31 (23)                   9 (24)                    33 (24)                   73 (24)
  Beth Israel Medical Centre, New York, U.S.A.[9](#acn3263-bib-0009){ref-type="ref"}, [15](#acn3263-bib-0015){ref-type="ref"}          20 (15)                   9 (24)                    33 (24)                   62 (20)
  University of Tubingen, Tubingen, Germany                                                                                            54 (41)                   10 (26)                   55 (40)                   119 (39)
  Cardiff University, Cardiff, United Kingdom[7](#acn3263-bib-0007){ref-type="ref"}                                                    27 (20)                   10 (26)                   16 (12)                   53 (17)

MC, manifesting carriers; NMC, nonmanifesting carriers; NC, noncarrier; SD, standard deviation.
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Methods {#acn3263-sec-0006}
=======

Movement disorder research groups that had previously published standardized and systematic psychiatric data from *SGCE* mutation‐positive M‐D cohorts were contacted and asked to provide a summary of their findings for each case. Each center was also asked to provide data from any as yet unpublished cases that could be included in analysis (Table [1](#acn3263-tbl-0001){ref-type="table-wrap"}; Fig. [1](#acn3263-fig-0001){ref-type="fig"}).

![Diagrammatic representation of case recruitment from the four international centers. MC, manifesting carrier; NMC, nonmanifesting carrier; NC, noncarrier; CIDI, Composite International Diagnostic Interview; M.I.N.I., MINI International Neuropsychiatric Interview; SCID‐I, Structured Clinical Interview.](ACN3-3-04-g001){#acn3263-fig-0001}

Standard protocol approvals, registrations and patient consents {#acn3263-sec-0007}
---------------------------------------------------------------

Ethical approval for data collection was obtained from the respective research and ethics committees in each of the recruiting countries (Netherlands, United Kingdom, United States and Germany). Written informed consent or assent was obtained from each participant or their parent/guardian prior to involvement in the study.

Genetic analysis {#acn3263-sec-0008}
----------------

As reported previously, DNA from all samples was analyzed by direct sequencing and Multiplex ligation‐dependent probe amplification (MLPA) of *SGCE* exons 1--12.[7](#acn3263-bib-0007){ref-type="ref"}, [8](#acn3263-bib-0008){ref-type="ref"}, [9](#acn3263-bib-0009){ref-type="ref"}, [14](#acn3263-bib-0014){ref-type="ref"}, [15](#acn3263-bib-0015){ref-type="ref"}

Clinical assessment {#acn3263-sec-0009}
-------------------

All cases underwent a neurological examination by a movement disorders expert at their original medical center and were classified according to their motor and genetic status into three groups: (1) manifesting carriers (MC): *SGCE* mutation and movement disorder (*n* = 132), (2) nonmanifesting carriers (NMC): *SGCE* mutation and no movement disorder (*n* = 38) and (3) noncarriers (NC): no *SGCE* mutation and no movement disorder (*n* = 137) (Table [1](#acn3263-tbl-0001){ref-type="table-wrap"}).

Psychiatric assessment {#acn3263-sec-0010}
----------------------

All centers used standardized assessment tools to establish lifetime psychiatric diagnoses according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM‐IV) criteria in their patient population. These included the Structured Clinical Interview (SCID‐I)[16](#acn3263-bib-0016){ref-type="ref"} (Netherlands), MINI International Neuropsychiatric Interview (M.I.N.I.)[17](#acn3263-bib-0017){ref-type="ref"} (Netherlands and United Kingdom) and Composite International Diagnostic Interview (CIDI)[18](#acn3263-bib-0018){ref-type="ref"} (United States and Germany) (Fig. [1](#acn3263-fig-0001){ref-type="fig"}). These included the sections on major affective disorder (MAD), generalized anxiety disorder (GAD), OCD, alcohol dependence, panic disorder, social phobia and specific phobia. Panic disorder, social phobia and specific phobia were not assessed amongst participants recruited in the United States and specific phobia was not assessed in those recruited from the United Kingdom. These cases were therefore excluded from the analysis of these disorders.

Data analysis and statistics {#acn3263-sec-0011}
----------------------------

Overall and disorder specific rates of psychiatric diagnoses were analyzed using chi‐squared and Fisher\'s exact testing where appropriate. Stepwise logistic regression and multilevel logistic regression were used to determine whether additional variables (age at examination, gender, center, questionnaire type) impacted upon the presence of psychiatric symptoms.

Results {#acn3263-sec-0012}
=======

Data from 307 cases (140 males and 167 females) with a mean age at examination of 42.5 years (±15.8 years) were analyzed. Subdivided according to genetic and motor criteria 132 MC, 38 NMC and 137 NC were included. There was a near equal sex distribution in MC and NMC subgroups, unlike those with no mutation (NC) where almost two‐thirds of the cases were female. Mean age at assessment was similar across MC and NC cohorts, while those in the NMC sub‐group were, on average, 10 years older. Half of all MC cases had onset of their motor symptoms at \<18 years of age, although this data was unknown in a similar number of cases (*n* = 68). Baseline motor, psychiatric and genetic data from each of the individual centers have been published previously, with the exception of those recruited by the University of Tubingen.[7](#acn3263-bib-0007){ref-type="ref"}, [8](#acn3263-bib-0008){ref-type="ref"}, [9](#acn3263-bib-0009){ref-type="ref"}, [14](#acn3263-bib-0014){ref-type="ref"}, [15](#acn3263-bib-0015){ref-type="ref"}

Sixty five percent of MC cases met DSM‐IV criteria for ≥1 psychiatric disorder, with rates of all disorder subtypes being above population estimates (Table [2](#acn3263-tbl-0002){ref-type="table-wrap"}). Specific phobias (33%), social phobia (31%) and MADs (30%) were the most common. Overall rates of psychiatric disorders were almost half that of population estimates in both NMC (21%) and NC (27%) cohorts. Symptoms consistent with MAD were the most commonly reported in both groups (NMC: 21%, NC: 27%) while alcohol dependence was the least common with no NMC cases and only 4 (3%) cases amongst nonmutation carriers.

###### 

Rate and type of psychiatric disorders in MC, NMC and NC cohorts

  Lifetime DSM‐IV disorder        MC, *n* (%) (*n* = 132)   NMC, *n* (%) (*n* = 38)   NC, *n* (%) (*n* = 137)   Total, *n* (%) (*n* = 307)   Population estimates (%)
  ------------------------------- ------------------------- ------------------------- ------------------------- ---------------------------- ---------------------------------------------
  Any DSM‐IV disorder             86 (65)                   8 (21)                    37 (27)                   131 (43)                     48[20](#acn3263-bib-0020){ref-type="ref"}
  Major affective disorder        40 (30)                   6 (16)                    20 (15)                   66 (21)                      17.1[20](#acn3263-bib-0020){ref-type="ref"}
  Generalized anxiety disorder    23 (17)                   1 (2.6)                   10 (7)                    34 (11)                      5.1[20](#acn3263-bib-0020){ref-type="ref"}
  Obsessive‐compulsive disorder   28 (21)                   1 (2.6)                   5 (4)                     34 (11)                      4[21](#acn3263-bib-0021){ref-type="ref"}
  Alcohol dependence              32 (24)                   0 (0)                     4 (3)                     36 (12)                      14.1[20](#acn3263-bib-0020){ref-type="ref"}
                                  (*n* = 112)               (*n* = 29)                (*n* = 104)               (*n* = 245)                  
  Panic disorder                  25 (22)                   1 (3)                     9 (9)                     35 (14)                      3.5[20](#acn3263-bib-0020){ref-type="ref"}
  Social phobia                   35 (31)                   1 (3)                     7 (7)                     43 (18)                      13.3[20](#acn3263-bib-0020){ref-type="ref"}
                                  (*n* = 85)                (*n* = 19)                (*n* = 88)                (*n* = 192)                  
  Specific phobia                 28 (33)                   1 (5)                     7 (8)                     36 (19)                      8.7[20](#acn3263-bib-0020){ref-type="ref"}

MC, manifesting carriers; NMC, non‐manifesting carriers; NC, non‐carrier; DSM‐IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition.
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Comparison of the motor affected MC group with the nonmutation carrying cohort (NC) found a significant difference in the overall rate of psychiatric disorders (OR 5.05, 95% confidence interval \[CI\] 2.91--8.80, *P* \< 0.001) as well as with each individual diagnosis. Alcohol dependence (OR 10.64, 95% CI 3.44--36.72, *P* \< 0.001) and OCD (OR 7.11, 95% CI 2.50--16.52, *P* \< 0.001) demonstrated the largest differences. Social and specific phobias were also significantly higher amongst the MC cases (*P* \< 0.001) (OR 6.30, 95% CI 2.50, 16.52 and OR 5.68, 95% CI 2.18, 15.44). In an attempt to determine whether *SGCE* mutations had a direct impact on psychiatric symptoms, NMC cases were compared to both the NC controls and motor affected (MC) cases. No significant difference was observed between NMC and NC patients either overall or with regard to individual diagnoses. However, comparison of MC and NMC participants found a significant difference in overall rates of psychiatric symptoms (OR 7.01, 95% CI 2.79--18.20, *P* \< 0.001) with the largest differences again being seen with alcohol dependence, OCD and social phobia, the latter two diagnoses being 10 and 12 times more likely, respectively, in the MC population. A full summary of analyses can be seen in Table [3](#acn3263-tbl-0003){ref-type="table-wrap"}. Sensitivity analyses using stepwise and multilevel logistic regression found no significant effect of age at examination, gender, center or questionnaire type upon rate of psychiatric symptoms.

###### 

Comparison of rates of psychiatric disorders between MC, NMC and NC cohorts

  Psychiatric diagnosis (DSM‐IV)   MC versus NC                       NMC versus NC             MC versus NMC
  -------------------------------- ---------------------------------- ------------------------- ---------------------------------
  Any DSM‐IV disorder              **\<0.001 (5.05; 2.91, 8.80)**     0.46 (0.72; 0.28, 1.83)   **\<0.001 (7.01; 2.79, 18.20)**
  Major affective disorder         **0.002 (2.54; 1.34, 4.86)**       0.86 (1.10; 0.36, 3.21)   0.10 (2.32; 0.84, 6.73)
  Generalized anxiety disorder     **0.011 (2.68; 1.15, 6.34)**       0.29 (0.34; 0.02, 2.76)   **0.02 (7.81; 1.06, 160.59)**
  Obsessive‐compulsive disorder    **\<0.001 (7.11; 2.50, 21.78)**    0.76 (0.71; 0.03, 6.63)   **0.007 (9.96; 1.37, 203.60)**
  Alcohol dependence               **\<0.001 (10.64; 3.44, 36.72)**   0.29 (0; 0, 5.65)         **0.001 (**∞; **2.38,** ∞**)**
  Panic disorder                   **0.006 (3.03; 1.26, 7.45)**       0.35 (0.38; 0.02, 3.14)   **0.02 (8.04; 1.07, 166.62)**
  Social phobia                    **\<0.001 (6.30; 2.50, 16.52)**    0.51 (0.50; 0.02, 4.32)   **0.002 (12.73; 1.73, 261.28)**
  Specific phobia                  **\<0.001 (5.68; 2.18, 15.44)**    0.68 (0.64; 0.03, 5.85)   **0.015 (8.84; 1.14, 186.62)**

Results analyzed using chi‐squared testing or Fisher\'s exact testing where appropriate. Results expressed as: *P*‐value (odds ratio, 95% confidence interval). Statistically significant results (*P* \< 0.05) are highlighted in bold. MC, manifesting carriers; NMC, non‐manifesting carriers; NC, non‐carrier; DSM‐IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition.
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Data relating to age at onset of both motor and psychiatric symptoms were available in 26 patients. Based on recall, none reported onset of psychiatric symptomatology prior to their comorbid motor features and the majority reported that their motor symptoms had begun clearly in advance of any subsequent psychiatric disorder. This was most commonly seen in relation to alcohol dependence (11/31). Twenty‐two cases reported near simultaneous onset of the motor symptoms and psychiatric symptoms, with MAD (7/22) and social phobia (6/22) being the most prevalent.

Discussion {#acn3263-sec-0013}
==========

This study represents the largest multicenter cohort of *SGCE* mutation‐positive M‐D patients investigated using systematic and standardized tools for psychiatric symptomatology. Consistent with previous studies, we have demonstrated an excess of psychiatric symptoms amongst motor affected mutation carriers (MC) compared to intrafamilial controls (NMC and NC), with alcohol dependence, OCD, social and specific phobias demonstrating the largest between group differences.[7](#acn3263-bib-0007){ref-type="ref"}, [9](#acn3263-bib-0009){ref-type="ref"} Some of the rarer psychiatric diagnoses, for example psychosis and anorexia, were not identified in this cohort suggesting that only a loose association exists between these rarer disorders and *SGCE* mutations.

The overall rate of psychiatric disorders was almost one and a half times greater in the MC (65%) cohort than population estimates (48%). These latter values were obtained from epidemiological studies in the United States[19](#acn3263-bib-0019){ref-type="ref"} and New Zealand[20](#acn3263-bib-0020){ref-type="ref"} and considered to be from comparable populations to our study cohort. Interestingly, overall rates of psychiatric diagnoses in the NMC (21%) and NC (27%) groups were only half that of the population controls. There is no clear explanation for this, although the relatively small group sizes, and an awareness of the impact of psychiatric disorders (for example alcohol excess in related MC family members) may in part account for these findings.

Excess alcohol dependence amongst *SGCE* mutation carriers has been consistently reported in previous studies.[7](#acn3263-bib-0007){ref-type="ref"}, [8](#acn3263-bib-0008){ref-type="ref"}, [15](#acn3263-bib-0015){ref-type="ref"} This was initially felt to be a secondary reactive response to the therapeutic effect of alcohol on motor symptoms.[2](#acn3263-bib-0002){ref-type="ref"}, [21](#acn3263-bib-0021){ref-type="ref"} More recent studies have suggested that *SGCE* may exert a gene independent effect in contributing to these symptoms,[6](#acn3263-bib-0006){ref-type="ref"}, [7](#acn3263-bib-0007){ref-type="ref"} potentially mirroring the mechanisms involved in OCD and compulsivity, also prevalent amongst this population.[7](#acn3263-bib-0007){ref-type="ref"} However, this study appears to support the former view of a therapeutic response rather than gene effect with a significant difference in alcohol consumption between MC and NMC groups (*P* = 0.001) compared to similar levels of intake in NMC and NC patients (*P* = 0.29). Similarly, in those where age at onset data for motor and psychiatric symptoms was available, a third of those with primary motor symptoms reported subsequent alcohol dependence (Table [4](#acn3263-tbl-0004){ref-type="table-wrap"}).

###### 

Relationship between age at onset of motor and psychiatric symptoms in MC cases

  Psychiatric diagnosis (DSM‐IV)   Motor symptoms as 1st symptom   Psychiatric symptoms as 1st symptom   Onset of motor and psychiatric symptoms at similar time point
  -------------------------------- ------------------------------- ------------------------------------- ---------------------------------------------------------------
  Major affective disorder         5                               0                                     7
  Generalized anxiety disorder     2                               0                                     3
  Obsessive‐Compulsive disorder    5                               0                                     3
  Alcohol dependence               11                              0                                     1
  Panic disorder                   4                               0                                     1
  Social phobia                    2                               0                                     6
  Specific phobia                  2                               0                                     1
  Total (*n*)                      31                              0                                     22

Data collected from only 26 patients where age relating to both features was known. Ages at onset placed into following categories: \<18, 19--30, 31--30, 41--50 and \>50 years. Simultaneous onset of symptoms was considered when both sets of symptoms began in the same age bracket. MC, manifesting carriers; DSM‐IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition.
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OCD was more prevalent amongst the MC group. As OCD is not typically considered a secondary response to a chronic, disabling disorder[22](#acn3263-bib-0022){ref-type="ref"} its relationship to M‐D and *SGCE* mutations continues to be of significant interest. However, there remains some conflict in this area with several previous publications reporting a strong association between *SGCE* mutations and OCD,[9](#acn3263-bib-0009){ref-type="ref"} in particular the compulsivity component,[7](#acn3263-bib-0007){ref-type="ref"} while others have reported no evidence of this in their cohort.[5](#acn3263-bib-0005){ref-type="ref"}, [8](#acn3263-bib-0008){ref-type="ref"} Similar results have been seen in mixed dystonia cohorts, some finding an excess of OCD when compared to disability matched and healthy controls[23](#acn3263-bib-0023){ref-type="ref"}, [24](#acn3263-bib-0024){ref-type="ref"}, [25](#acn3263-bib-0025){ref-type="ref"} while others have found no evidence of an association.[26](#acn3263-bib-0026){ref-type="ref"} In M‐D this may represent a pleiotropic function of *SGCE* mutations for the development of both motor and OC symptoms at an age of increased vulnerability to these symptoms.

Anxiety‐related disorders have been widely published in previous M‐D cohorts.[8](#acn3263-bib-0008){ref-type="ref"}, [13](#acn3263-bib-0013){ref-type="ref"}, [27](#acn3263-bib-0027){ref-type="ref"} However, GAD was the least common psychopathology (17%) in this cohort, and although significant, showed the smallest difference when compared to both NMC and NC groups. This may be explained by generalized anxiety and related disorders (panic disorder, social and specific phobias) being analyzed separately in this study, rather than collectively as has been done previously. Although focal dystonia and anxiety‐related symptoms have been postulated to share a common pathophysiological pathway[28](#acn3263-bib-0028){ref-type="ref"} debate remains as to whether this is a primary or secondary effect of the movement disorder. Suggesting a primary mechanism, several studies have reported onset of the anxiety symptoms prior to the movement disorder.[29](#acn3263-bib-0029){ref-type="ref"}, [30](#acn3263-bib-0030){ref-type="ref"} However, both studies involved mixed groups of focal dystonia, limiting interpretation of the results. In our smaller cohort, near equal numbers reported onset of their anxiety‐related disorder either in conjunction with (11 cases) or subsequent (10 cases) to development of their motor symptoms.

In this study, as with previous publications, we attempted to determine whether *SGCE* mutations exerted a gene independent effect in contributing to psychiatric symptomatology, a finding that could have significant implications to our understanding of underlying pathophysiological mechanisms. No evidence of this was found with exception of the lack of a statistically significant difference in the rate of MAD between MC and NMC groups. However, there was no significant difference between NMC and NC groups either and therefore this is unlikely to represent an independent effect of *SGCE* mutations. As with almost all previous studies[7](#acn3263-bib-0007){ref-type="ref"}, [15](#acn3263-bib-0015){ref-type="ref"} our attempts to identify a pleiotropic role for *SGCE* were limited by the small size of the NMC cohort. However, it is also important to consider that manifestation of psychiatric symptoms, as is seen with the motor features, may be similarly silenced due to the imprinting mechanism in the presence of pathogenic mutations.

The use of different psychiatric assessments both between and within individual centere represents a potential limitation of this study. Although all allow classification of symptoms according to DSM‐IV criteria, the manner in which this is achieved differs between interviews. There is, however, evidence to suggest strong concordance between SCID‐I and MINI questionnaires,[17](#acn3263-bib-0017){ref-type="ref"} while the CIDI is designed for epidemiological studies and demonstrates greater sensitivity. These interviews were also administered by a number of different assessors with differing training backgrounds. However, the standardized and systematic nature of all three questionnaires limits the potential impact of personal bias and represents the most pragmatic means of assessing a large population across several countries. Finally, although much of the standardized data collection referred to lifetime and present diagnosis, age at onset for example was retrospectively collected and therefore may be limited by recall bias. A systematic prospective data collection in families of affected probands, starting at an early age, remains the only means to overcome this potential bias and given the rarity of this disorder a multicenter international collaboration would provide an opportunity to investigate this further.

Conclusion {#acn3263-sec-0014}
==========

We have demonstrated a higher incidence of psychiatric disorders in the motor affected *SGCE* mutation carriers compared to nonmutation carrying familial controls in the largest published cohort to date. Alcohol dependence, OCD, social and specific phobias were the most strongly associated disorders, consistent with the findings from previous smaller studies. Although no gene independent role for *SGCE* was demonstrated in this cohort, the consistent finding of comorbid psychiatric disorders within M‐D cohorts suggests that in its active mutated form, *SGCE* contributes to both motor and psychiatric symptoms. Further prospective work following affected probands and family members from an early age is required to clarify the temporal pattern of onset of these symptoms, how they relate to one another, and what implications this may have on our understanding of the pathogenesis of this disorder.
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